News & Updates

Show Multimedia Only

Topiramate tied to weight loss vs other antiseizure drugs

06 Jan 2026

Among commonly used antiseizure medications (ASMs), topiramate appears to result in weight loss at 6 and 12 months under either initiation and subsequent adherence or initiation-only effects, reports a study. Other ASMs seem to contribute to greater weight change.

Topiramate tied to weight loss vs other antiseizure drugs

06 Jan 2026

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

06 Jan 2026 by

In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

06 Jan 2026

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-December-2025

06 Jan 2026

New drug applications approved by US FDA as of 1-15 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-December-2025

06 Jan 2026

Original New Drug Application Approvals by US FDA (16-31 December 2025)

06 Jan 2026

New drug applications approved by US FDA as of 16-31 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2025)

06 Jan 2026

4-week ustekinumab dosing revs up response in Crohn’s disease

05 Jan 2026 by

For Crohn’s disease (CD) patients with suboptimal response to ustekinumab, doubling the dosing frequency from every 8 weeks to every 4 weeks elicited meaningful improvements in objective and patient-reported outcomes, as shown in a small retrospective study.

4-week ustekinumab dosing revs up response in Crohn’s disease

05 Jan 2026

Original New Drug Application Approvals by US FDA (16-30 November 2025)

05 Jan 2026

New drug applications approved by US FDA as of 16-30 November 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2025)

05 Jan 2026

Antiviral therapy prevents recurrence in CMV-AU

04 Jan 2026

A recent study has observed a very high recurrence rate for cytomegalovirus (CMV) anterior uveitis (AU), but this can be resolved by antiviral therapy.

Antiviral therapy prevents recurrence in CMV-AU

04 Jan 2026

Race, age linked to anti-VEGF initiation for nAMD

02 Jan 2026 by

One in five patients with neovascular age-related macular degeneration (nAMD) fail to start treatment within 1 year of presentation, reports a study. Factors associated with lower treatment initiation include Asian race, age <60 years, and low-vision status, among others.